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The effect of atypical antipsychotics on brain 
N-acetylaspartate levels in antipsychotic-naïve 
first-episode patients with schizophrenia:  
a preliminary study
Purpose: To investigate the correlates of a clinical therapeutic response by using the param-
eters measured by proton magnetic resonance spectroscopy after the administration of atypical 
antipsychotics.
Patients and methods: Twenty-five antipsychotic-naïve first-episode patients with schizo-
phrenia were monitored for 12 months. The patients were evaluated using 1H magnetic reso-
nance spectroscopy in the dorsolateral prefrontal cortex and Positive and Negative Syndrome 
Scale, Clinical Global Impression Scale of Severity, Tower of London – Drexel University, 
Letter–Number Span Test, Trail Making Test A, and Personal and Social Performance Scale. 
They were administered atypical antipsychotics, starting with quetiapine. In the absence of a 
therapeutic response, another antipsychotic was introduced.
Results: After 12 study months, the N-acetylaspartate/creatine (NAA/Cr) level did not signifi-
cantly change at the whole-group level. Additional analysis revealed a significant rise in the NAA/
Cr level in the study group that stayed on the same antipsychotic throughout the study course 
(P=0.008) and a significant drop in NAA/Cr in the study group that switched antipsychotics 
(P=0.005). On the whole-group level, no significant correlations between NAA/Cr values and 
other scores were found at either baseline or after 12 study months.
Conclusion: One-year treatment with atypical antipsychotics administered to antipsychotic-
naïve patients didn’t result in a significant rise in the NAA/Cr ratio. However, a significant rise 
was witnessed in the study group in which a satisfactory therapeutic response had been achieved 
with a single antipsychotic administration.
Keywords: schizophrenia, atypical antipsychotics, NAA, MRS
Introduction
N-acetylaspartate (NAA) is considered to be the marker of neuron dysfunction and/or 
loss.1–3 Akin to the level of creatine (Cr) plus phosphocreatine and some other brain 
metabolites, the NAA level can be determined using in vivo proton magnetic resonance 
spectroscopy (1H MRS). Upon the cessation of an adverse impact or treatment, the 
NAA level may prove itself reversible.4–7
A meta-analysis that compared NAA levels in patients with schizophrenia and 
healthy controls found significant NAA reductions in the frontal lobe and hippocam-
pus in patients with schizophrenia. Many authors consider that decreased NAA levels 
might be a biomarker for neurological diseases. The main results are presented in 
Table 1.8–31 NAA changes occur in the early stage of illness. No further decrease in 
the NAA level was found among chronic patients.9,10
Journal name: Neuropsychiatric Disease and Treatment
Journal Designation: Original Research
Year: 2014
Volume: 10
Running head verso: Grošic´ et al
Running head recto: N-acetylaspartate in patients with schizophrenia
DOI: http://dx.doi.org/10.2147/NDT.S61415
Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1244
grošic´ et al
T
ab
le
 1
 r
ev
ie
w
 o
f p
re
vi
ou
s 
st
ud
ie
s
A
ut
ho
r
A
nt
ip
sy
ch
ot
ic
s
D
ur
at
io
n
M
et
ho
ds
M
ai
n 
re
su
lt
s
st
ee
n 
et
 a
l (
20
06
)8
D
ru
g 
na
ïv
e
sy
st
em
at
ic
 r
ev
ie
w
 a
nd
 m
et
a-
an
al
ys
is
W
ho
le
 b
ra
in
 a
nd
 h
ip
po
ca
m
pa
l v
ol
um
e 
w
er
e 
re
du
ce
d
Fa
nn
on
 e
t 
al
 (
20
03
)9
H
al
op
er
id
ol
, o
la
nz
ap
in
e,
 r
is
pe
ri
do
ne
3 
m
on
th
s
Fi
rs
t-
ep
is
od
e,
 1 h
 M
r
s,
 N
a
a
/c
r,
 a
nt
ip
sy
ch
ot
ic
s 
 
at
 b
as
el
in
e 
an
d 
af
te
r 
3 
m
on
th
s
A
 s
ig
ni
fic
an
t 
re
du
ct
io
n 
in
 h
ip
po
ca
m
pa
l N
A
A
/C
r
Bu
st
ill
o 
et
 a
l (
20
08
)1
0
h
al
op
er
id
ol
, q
ue
tia
pi
ne
2 
ye
ar
s
1 h
 M
r
s,
 fr
on
ta
l a
nd
 o
cc
ip
ita
l l
ob
es
, c
au
da
te
  
nu
cl
eu
s,
 a
nd
 c
er
eb
el
lu
m
T
yp
ic
al
 o
r 
at
yp
ic
al
 a
nt
ip
sy
ch
ot
ic
s 
di
d 
no
t 
re
su
lt 
in
 
N
a
a
 c
ha
ng
es
li
eb
er
m
an
 e
t 
al
 (
20
05
)1
1
H
al
op
er
id
ol
, o
la
nz
ap
in
e
10
4 
w
ee
ks
1 h
 M
r
s 
as
se
ss
m
en
ts
 p
er
fo
rm
ed
 a
t 
w
ee
ks
 0
, 1
2,
  
24
, 5
2,
 a
nd
 1
04
H
al
op
er
id
ol
 h
ad
 s
ig
ni
fic
an
t 
de
cr
ea
se
s 
in
 g
ra
y 
m
at
te
r 
vo
lu
m
e;
 o
la
nz
ap
in
e 
di
d 
no
t
li
nd
qu
is
t 
et
 a
l (
20
00
)1
2
H
al
op
er
id
ol
, c
lo
za
pi
ne
, o
la
nz
ap
in
e
1 
w
ee
k
in
 v
iv
o 
1 h
 M
r
s,
 4
.7
 T
 (
an
im
al
s)
N
o 
si
gn
ifi
ca
nt
 c
ha
ng
es
 in
 N
A
A
/C
r
Bu
st
ill
o 
et
 a
l (
20
04
)1
3
H
al
op
er
id
ol
, c
lo
za
pi
ne
6 
w
ee
ks
T
hr
ee
 g
ro
up
s 
tr
ea
te
d 
w
ith
 a
nt
ip
sy
ch
ot
ic
s 
or
  
ve
hi
cl
e/
6 
w
ee
ks
. N
a
a
 w
er
e 
de
te
rm
in
ed
 b
y 
 
h
Pl
c
 (
an
im
al
s)
N
o 
di
ffe
re
nc
es
 in
 N
a
a
 in
 c
or
te
x,
 s
tr
ia
tu
m
, a
nd
 
th
al
am
us
 c
om
pa
re
d 
to
 a
ni
m
al
s 
tr
ea
te
d 
w
ith
 
ve
hi
cl
e
h
ar
te
 e
t 
al
 (
20
05
)1
4
h
al
op
er
id
ol
 d
ec
an
oa
te
24
 w
ee
ks
M
ea
su
re
d 
N
a
a
 in
 b
ra
in
 t
is
su
e 
ta
ke
n 
fr
om
  
43
 m
al
es
N
a
a
 in
cr
ea
se
d 
in
 t
he
 s
tr
ia
tu
m
M
cl
ou
gh
lin
 e
t 
al
 (
20
09
)1
5
H
al
op
er
id
ol
, c
lo
za
pi
ne
, o
la
nz
ap
in
e,
  
ri
sp
er
id
on
e,
 a
ri
pi
pr
az
ol
e
M
et
ab
ol
ite
s 
w
er
e 
de
te
rm
in
ed
 u
si
ng
 1 h
 M
r
s
A
nt
ip
sy
ch
ot
ic
s,
 w
ith
 t
he
 e
xc
ep
tio
n 
of
 o
la
nz
ap
in
e,
 
co
ns
is
te
nt
ly
 in
cr
ea
se
d 
N
a
a
 le
ve
ls
 in
 a
t 
le
as
t 
 
on
e 
br
ai
n 
ar
ea
Bu
st
ill
o 
et
 a
l (
20
06
)1
6
h
al
op
er
id
ol
 d
ec
an
oa
te
6 
m
on
th
s
1 h
 M
r
s 
at
 1
1.
7 
T
 in
 e
x 
vi
vo
, m
ed
ia
l f
ro
nt
al
 a
nd
  
ci
ng
ul
at
e 
co
rt
ex
, s
tr
ia
tu
m
, n
uc
le
us
 a
cc
um
be
ns
,  
do
rs
al
 a
nd
 v
en
tr
al
 h
ip
po
ca
m
pu
s,
 a
m
yg
da
la
,  
an
d 
te
m
po
ra
l c
or
te
x 
(a
ni
m
al
s)
D
id
 n
ot
 r
es
ul
t 
in
 c
ha
ng
es
 in
 N
a
a
, g
lu
ta
m
at
e,
 
gl
ut
am
in
e,
 a
nd
 o
th
er
 m
et
ab
ol
ite
s 
in
 t
he
 p
ro
to
n 
sp
ec
tr
um
li
nd
qu
is
t 
et
 a
l (
20
11
)1
7
H
al
op
er
id
ol
, c
lo
za
pi
ne
6 
m
on
th
s
1 h
 M
r
s,
 6
 m
on
th
s,
 N
a
a
, c
r,
 a
nd
 c
ho
 (
an
im
al
s)
O
nl
y 
th
e 
C
ho
/C
r 
ra
tio
 s
ho
w
ed
 a
 s
ig
ni
fic
an
t 
 
tim
e-
by
-t
re
at
m
en
t 
ef
fe
ct
Be
rt
ol
in
o 
et
 a
l (
20
01
)1
8
C
lo
za
pi
ne
, r
is
pe
ri
do
ne
, h
al
op
er
id
ol
,  
flu
ph
en
az
in
e,
 t
ri
flu
op
er
az
in
e,
 o
la
nz
ap
in
e,
  
th
io
th
ix
en
e,
 m
es
or
id
az
in
e
1 h
 M
r
s 
st
ud
ie
d 
tw
ic
e,
 D
lP
Fc
Pa
tie
nt
s 
on
 a
nt
ip
sy
ch
ot
ic
s 
ha
d 
si
gn
ifi
ca
nt
ly
 h
ig
he
r 
N
a
a
 m
ea
su
re
s 
in
 t
he
 D
lP
Fc
Bu
st
ill
o 
et
 a
l (
20
10
)1
9
Q
ue
tia
pi
ne
, r
is
pe
ri
do
ne
, h
al
op
er
id
ol
,  
cl
oz
ap
in
e
12
 m
on
th
s
1 h
 M
r
s 
of
 t
he
 a
c
, f
ro
nt
al
 w
hi
te
 m
at
te
r,
 a
nd
  
th
al
am
us
 a
t 
4 
T
. N
a
a
, g
lu
, g
ln
, a
nd
 g
ln
/g
lu
N
a
a
 r
ed
uc
tio
ns
 a
nd
 c
or
re
la
te
d 
el
ev
at
io
ns
 o
f g
ln
/
G
lu
 in
 t
he
 A
C
 a
re
 p
re
se
nt
 e
ar
ly
 in
 s
ch
iz
op
hr
en
ia
Br
au
s 
et
 a
l (
20
02
)2
0
T
ra
di
tio
na
l n
eu
ro
le
pt
ic
s 
an
d 
at
yp
ic
al
  
an
tip
sy
ch
ot
ic
s
N
a
a
 w
as
 c
lo
se
ly
 c
or
re
la
te
d 
w
ith
 p
er
se
ve
ra
tio
n 
 
er
ro
rs
 s
ee
n 
on
 t
he
 W
c
sT
a
ty
pi
ca
l a
nt
ip
sy
ch
ot
ic
s 
m
od
ify
 t
he
 fu
nc
tio
n 
of
 
an
te
ri
or
 c
in
gu
la
te
 n
eu
ro
ns
 (
im
pr
ov
e 
co
gn
iti
ve
 
fu
nc
tio
n)
Bu
st
ill
o 
et
 a
l (
20
01
)2
1
H
al
op
er
id
ol
, c
lo
za
pi
ne
T
re
at
ed
 p
at
ie
nt
s 
an
d 
no
rm
al
 c
on
tr
ol
s,
 1 h
 M
r
s 
 
of
 t
he
 c
au
da
te
 n
uc
le
i a
nd
 t
he
 le
ft 
fr
on
ta
l l
ob
e
ex
po
su
re
 t
o 
ha
lo
pe
ri
do
l l
ed
 t
o 
fr
on
ta
l N
a
a
 
re
du
ct
io
ns
 p
re
vi
ou
sl
y 
re
po
rt
ed
 in
 s
ch
iz
op
hr
en
ia
Sz
ul
c 
et
 a
l (
20
07
)2
2
Pe
rp
he
na
zi
ne
, p
er
az
in
e,
 h
al
op
er
id
ol
,  
cl
oz
ap
in
e,
 o
la
nz
ap
in
e,
 r
is
pe
ri
do
ne
1 h
 M
r
s,
 v
ox
el
s 
of
 2
×2
×2
 c
m
, l
ef
t 
fr
on
ta
l, 
le
ft 
 
te
m
po
ra
l l
ob
e,
 a
nd
 le
ft 
th
al
am
us
D
ec
re
as
e 
in
 N
a
a
 d
ue
 t
o 
ty
pi
ca
l m
ed
ic
at
io
n 
m
ay
 
be
 c
au
se
d 
by
 t
he
 p
ro
gr
es
si
on
 o
f t
he
 d
is
ea
se
, 
pr
ev
io
us
 d
ru
g 
hi
st
or
y,
 o
r 
by
 d
ru
gs
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1245
N-acetylaspartate in patients with schizophrenia
Y
eo
 e
t 
al
 (
20
00
)2
3
1 h
 M
r
s,
 r
ig
ht
 fr
on
ta
l w
hi
te
 m
at
te
r,
 v
is
ua
l  
tw
o-
ba
ck
 t
es
t 
as
se
ss
ed
 w
or
ki
ng
 m
em
or
y
c
r 
an
d 
N
a
a
 p
os
iti
ve
ly
 c
or
re
la
te
d 
w
ith
 w
or
ki
ng
 
m
em
or
y 
sk
ill
s
V
al
en
zu
el
a 
et
 a
l (
20
00
)2
4
N
a
a
, f
ro
nt
al
 s
ub
co
rt
ic
al
 w
hi
te
 m
at
te
r,
 a
nd
 t
he
  
oc
ci
pi
to
pa
ri
et
al
 g
ra
y 
m
at
te
r 
co
rr
el
at
ed
 w
ith
  
pe
rf
or
m
an
ce
 in
 d
iff
er
en
t 
co
gn
iti
ve
 d
om
ai
ns
N
eu
ro
m
et
ab
ol
ic
 fi
tn
es
s 
of
 t
he
 fr
on
ta
l s
ub
co
rt
ic
al
–
co
rt
ic
al
 a
xo
na
l fi
be
rs
 m
ay
 b
e 
im
po
rt
an
t 
in
 
m
ed
ia
tin
g 
flu
id
 in
te
lle
ct
ua
l p
ro
ce
ss
in
g
Be
rt
ol
in
o 
et
 a
l (
20
03
)2
5
su
bj
ec
ts
 u
nd
er
w
en
t 
1 h
 M
r
s 
an
d 
w
er
e 
gi
ve
n 
 
th
e 
N
-b
ac
k 
w
or
ki
ng
 m
em
or
y 
te
st
r
ed
uc
tio
ns
 o
f N
a
a
 in
 t
he
 h
ip
po
ca
m
pa
l a
re
a 
an
d 
D
lP
Fc
, p
os
iti
ve
 c
or
re
la
tio
n 
be
tw
ee
n 
N
a
a
 in
 t
he
 
D
lP
Fc
 a
nd
 p
er
fo
rm
an
ce
 d
ur
in
g 
th
e 
tw
o-
ba
ck
 
w
or
ki
ng
 m
em
or
y 
co
nd
iti
on
Be
rt
ol
in
o 
et
 a
l (
20
00
)2
6
1 h
 M
r
s,
 N
a
a
, a
nd
 P
eT
 d
ur
in
g 
pe
rf
or
m
an
ce
  
of
 t
he
 W
c
sT
N
a
a
 in
 t
he
 D
lP
Fc
 s
tr
on
gl
y 
co
rr
el
at
ed
 w
ith
 
ac
tiv
at
io
n 
of
 t
he
 d
is
tr
ib
ut
ed
 w
or
ki
ng
 m
em
or
y 
ne
tw
or
k
T
an
ak
a 
et
 a
l (
20
06
)2
7
1 h
 M
r
s,
 le
ft 
fr
on
ta
l l
ob
e 
in
 1
4 
pa
tie
nt
s 
w
ith
  
sc
hi
zo
ph
re
ni
a 
an
d 
in
 1
3 
he
al
th
y 
co
m
pa
ri
so
n 
 
su
bj
ec
ts
D
ec
re
as
ed
 N
a
a
 in
 t
he
 le
ft 
fr
on
ta
l l
ob
e 
of
 
pa
tie
nt
s 
w
as
 c
or
re
la
te
d 
w
ith
 n
eg
at
iv
e 
sy
m
pt
om
s 
an
d 
co
gn
iti
ve
 d
ys
fu
nc
tio
n
Br
ac
ke
n 
et
 a
l (
20
13
)2
8
1 h
 M
r
s 
re
po
rt
in
g 
m
ea
su
re
m
en
ts
 o
f N
a
a
 in
 
sc
hi
zo
ph
re
ni
a 
w
ith
 fo
cu
s 
of
 m
et
ho
do
lo
gy
lo
w
er
 N
a
a
 m
or
e 
lik
el
y 
to
 h
av
e 
us
ed
 lo
ng
er
 
ec
ho
 t
im
es
 (
T
es
), 
w
hi
le
 s
tu
di
es
 w
ith
 s
ho
rt
er
 T
es
 
re
po
rt
ed
 n
o 
ch
an
ge
r
ei
d 
et
 a
l (
20
13
)2
9
1 h
 M
r
s 
to
 q
ua
nt
ify
 le
ve
ls
 o
f N
a
a
, g
lu
, g
lx
,  
an
d 
c
ho
 in
 t
he
 le
ft 
su
bs
ta
nt
ia
 n
ig
ra
N
o 
di
ffe
re
nc
es
 in
 le
ve
ls
 o
f N
a
a
/c
r,
 g
lx
/c
r,
 
or
 C
ho
/C
r 
be
tw
ee
n 
th
e 
gr
ou
ps
. S
ig
ni
fic
an
t 
co
rr
el
at
io
n 
be
tw
ee
n 
g
lx
/c
r 
an
d 
ov
er
al
l c
og
ni
tiv
e 
pe
rf
or
m
an
ce
Sz
ul
c 
et
 a
l (
20
13
)3
0
r
ev
ie
w
ed
 2
7 
st
ud
ie
s,
 1
6 
be
fo
re
/a
fte
r 
tr
ea
tm
en
t 
 
an
d 
11
 c
ro
ss
-s
ec
tio
na
l a
bo
ut
 a
nt
ip
sy
ch
ot
ic
s 
in
  
sc
hi
zo
ph
re
ni
a 
an
d 
N
A
A
 a
lte
ra
tio
ns
a
nt
ip
sy
ch
ot
ic
s 
m
ay
 a
ct
 b
y 
in
cr
ea
si
ng
 N
a
a
 
le
ve
ls
 in
 s
el
ec
te
d 
br
ai
n 
ar
ea
s 
(fr
on
ta
l l
ob
e 
an
d 
th
al
am
us
), 
es
pe
ci
al
ly
 d
ur
in
g 
th
e 
sh
or
t-
tim
e 
ob
se
rv
at
io
n
Sz
ul
c 
et
 a
l (
20
12
)3
1
PA
N
SS
, C
G
I, 
W
C
ST
, T
M
T
, v
er
ba
l fl
ue
nc
y 
te
st
,  
an
d 
1 h
 M
r
s 
w
er
e 
pe
rf
or
m
ed
. r
eg
io
ns
: l
ef
t 
fr
on
ta
l, 
te
m
po
ra
l, 
th
al
am
us
. M
et
ab
ol
ite
s:
 N
a
a
, c
ho
,  
m
yo
-in
os
ito
l, 
g
lx
c
or
re
la
tio
n 
be
tw
ee
n 
W
c
sT
, n
eg
at
iv
e 
sy
m
pt
om
s 
sc
or
e,
 e
du
ca
tio
n 
le
ve
l, 
an
d 
m
yo
-in
os
ito
l 
ra
tio
 in
 t
he
 fr
on
ta
l l
ob
e;
 r
ol
e 
of
 t
he
 t
ha
la
m
us
 
“t
ra
ns
m
is
si
on
 s
ta
tio
n”
 fo
r 
ps
yc
ho
pa
th
ol
og
y 
de
ve
lo
pm
en
t 
(e
sp
ec
ia
lly
 n
eg
at
iv
e)
 in
 s
ch
iz
op
hr
en
ia
A
bb
re
vi
at
io
ns
: 1
h
 M
r
s,
 p
ro
to
n 
m
ag
ne
tic
 r
es
on
an
ce
 s
pe
ct
ro
sc
op
y;
 a
c
, a
nt
er
io
r 
ci
ng
ul
at
e;
 c
g
i, 
c
lin
ic
al
 g
lo
ba
l i
m
pr
es
si
on
 s
ca
le
; c
ho
, c
ho
lin
e;
 c
r,
 c
re
at
in
e;
 D
lP
Fc
, d
or
so
la
te
ra
l p
re
fr
on
ta
l c
or
te
x;
 g
ln
, g
lu
ta
m
in
e;
 g
lu
, g
lu
ta
m
at
e;
 g
lx
, 
gl
ut
am
in
e 
pl
us
 g
lu
ta
m
at
e;
 h
Pl
c
, h
ig
h-
pe
rf
or
m
an
ce
 li
qu
id
 c
hr
om
at
og
ra
ph
y;
 N
a
a
, N
-a
ce
ty
la
sp
ar
ta
te
; P
a
N
ss
, P
os
iti
ve
 a
nd
 N
eg
at
iv
e 
sy
nd
ro
m
e 
sc
al
e;
 P
eT
, p
os
itr
on
 e
m
is
si
on
 t
om
og
ra
ph
y;
 T
M
T
, T
ra
il 
M
ak
in
g 
T
es
t; 
W
c
sT
, W
is
co
ns
in
 c
ar
d 
so
rt
in
g 
T
es
t; 
T
, T
es
la
; N
-b
ac
k,
 N
-b
ac
k 
w
or
ki
ng
 m
em
or
y 
te
st
.
Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1246
grošic´ et al
The aim of this study was to investigate the correlates 
of a clinical therapeutic response by using the parameters 
measured by 1H MRS after the administration of atypical 
antipsychotics. The specific aim was to establish the influence 
of atypical antipsychotics on the NAA/Cr ratio in the dorso-
lateral prefrontal cortex of antipsychotic-naїve first-episode 
patients with schizophrenia, as well as to investigate the 
relationship between the NAA/Cr ratio and positive, negative, 
and cognitive symptoms and functioning of patients.
Materials and methods
Patients
The study enrolled patients diagnosed with schizophrenia 
and schizophreniform disorder in line with Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition 
 criteria.32 Throughout the follow-up course, all patients were 
expected to meet the diagnostic criteria observed with schizo-
phrenia. Patients were recruited from the pool of consecutive 
outpatients seen by the Polyclinic Neuron (Zagreb, Croatia) 
and were all antipsychotic-naїve at the time of the first scan. 
All the patients had regular checkups. No psychotherapy 
was performed.
Exclusion criteria were: other psychiatric disorders, 
neurological disorders, a history of significant drug abuse, 
drug use in the past year, pregnancy and lactation, major 
somatic conditions, head trauma that rendered the patient 
unconscious, risk of suicide as estimated by the Columbia 
Suicide Severity Rating Scale,33 and the incapacity to give 
informed consent. No brain atrophy or other brain morphol-
ogy alteration was seen on any baseline MR imaging. Upon 
being thoroughly informed about the study concept, the 
patients gave their written informed consent. The study was 
approved by the institutional Board of Ethics.
Follow-up procedure
Two MR imaging scans were completed; the first one took 
place at baseline and the second one was scheduled for the 
end of the 1-year follow-up period (±1 month). Prior to each 
scan, the patients were administered 5–10 mg diazepam. 
Throughout the follow-up course, patients were admin-
istered antipsychotics in line with the study protocol. At 
first, quetiapine (400–800 mg QD) was introduced. In cases 
where a treatment response was not seen within 3 months – 
despite dose adjustments (as established using adequate 
scales), olanzapine (10–20 mg QD) was introduced. In cases 
where the above history repeated itself, olanzapine was first 
replaced by risperidone (2–8 mg QD) and then by clozapine 
(100–900 mg QD).
The study was initially comprised of 30 patients. 
Two of them were subsequently excluded after they had an 
overwhelming fear response that prevented the completion 
of either the first or second scan. One examinee withdrew his 
informed consent, while one witnessed a major deterioration 
and had to be hospitalized, rendering him unable to complete 
the study. Following the first scan, one examinee suffered an 
injury to his eye caused by metal foreign body penetration. 
This injury necessitated his departure from the study. The 
study was completed by 25 examinees. Upon the study’s 
completion, ten patients were treated with quetiapine, ten 
with olanzapine, and four with risperidone, while clozapine 
was not taken by any of the patients. Despite the study’s pro-
tocol, in the single case where a patient developed metabolic 
syndrome, ziprasidone had to be introduced.
instruments
Both at baseline and at every 3 months for the remainder of 
the study, the following tests were administered: Positive 
and Negative Syndrome Scale (PANSS)34 applicable for 
psychopathology, Clinical Global Impression of Severity 
(CGI-S)35 suitable for the determination of severity level, 
Tower of London – Drexel University (TOL DX),36 Trail 
Making Test A (TMT-A)37 and Letter–Number Span Test 
(LN)38 suitable for swift neuropsychological assessment, and 
Personal and Social Performance Scale (PSP)39 suitable for 
the determination of functionality level.
PANSS consists of positive, negative, and general 
 psychopathology scales. For TOL DX, which is viewed as the 
executive functions test, the examinee is required to move sev-
eral differently colored beads across three pegs in line with a 
predestined pattern, making as few moves as possible. Within 
the frame of TMT-A, which is viewed as the visual attention 
test, the examinee is asked to connect randomly arranged 
numbers in their sequential order. LN, which is considered 
to be a working memory test, requires the examinee to sort 
relatively short sequences of randomly presented letters and 
numbers in both sequential and alphabetic order.
Treatment response was evaluated using CGI-S and CGI 
of Improvement35 every 3 months. In addition, the Simpson–
Angus Scale40 for parkinsonism, Abnormal Involuntary Move-
ments Scale41 for tardive dyskinesia, and the Barnes Akathisia 
Rating Scale42 for akathisia were used every 3 months.
1h Mrs
Patients were scanned using a 3T MR device (Magnetom® 
Trio; Siemens AG, Erlangen, Germany) equipped with a 
12-channel head coil suitable for MRS. Standard T1 and 
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T2 sequences completed in the coronal, sagittal, and axial 
plane and covering the entire brain were acquired for each 
subject to the effect of spectral localization and exclusion of 
possible structural brain damage. The spectroscopic volume 
of interest, having a size of 15×15×15 mm, was selected in 
the left dorsolateral prefrontal cortex region (Figure 1) so 
as to minimize the amount of cerebrospinal fluid contained 
in the volume of interest.
Given the fact that the patients’ profiles called for shorter 
scanning times, the left dorsolateral prefrontal cortex, which 
is the brain area frequently targeted by other authors as well, 
was focused on. Single-voxel spectra were acquired using a 
point-resolved spectroscopy; the echo time equaled 135 mil-
liseconds, with a repetition time of 2,000 milliseconds and 
a spectral width of 10 ppm. The target area was scanned 
128 times on average with a scanning time of 4:17 minutes. 
An appropriate automated procedure was used to optimize 
field homogeneity, radiofrequency pulse power, and water 
suppression, as well as to convert the lines into a Gaussian 
shape. A typical 1H MRS spectrum is shown in Figure 1. 
By virtue of the foregoing, integral values of NAA and Cr 
peaks were obtained, while NAA/Cr ratios were used for 
further analysis.
statistical analysis
The Smirnov–Kolmogorov test was used to analyze data 
distribution. Due to the nature of the findings and a relatively 
small sample size, nonparametric tests were employed with 
other analyses. Medians and corresponding interquartile 
ranges were used to describe quantitative values. Differences 
in antipsychotic drug use and quantitative scores (PANSS, 
CGI-S, TOL DX, LN, TMT-A, and PSP scores and NAA/Cr 
values) seen between the study groups, were analyzed using the 
Mann–Whitney U test. The Wilcoxon test was used to assess 
differences between quantitative variables seen at the beginning 
and at the end of the study (after 12 months). Spearman’s cor-
relation coefficients (rho) were calculated so as to analyze the 
correlation between MR findings and test scores. All P-values 
lower than 0.05 were considered statistically significant. 
All statistical analyses made use of IBM SPSS® Statistics 
 version 19.0.0.1 (IBM Corporation, Armonk, NY, USA).
Results
Twenty-five patients were monitored for 12 months: 
15 (60.0%) had used more than one antipsychotic drug. The 
majority of patients were men (20; 80.0%). The educational 
background of the study group was as follows: 16 exam-
inees (64.0%) had 12 years of formal education. Thirteen 
patients (52.0%) were unemployed, 17 (68.0%) were single, 
and 18 (72.0%) declared themselves tobacco smokers. All 
patients were right-handed.
Viewed on the whole-group level, no significant NAA/
Cr changes were seen after 12 months of study (P=0.668). 
The subsequent analysis embraced two distinctive patient 
groups: one included patients who – due to their favorable 
and swift therapeutic response – remained on initial que-
tiapine therapy throughout the study course, and the other 
included patients who, within the same timeframe, had 
to be administered two or more atypical antipsychotics. 
There were no significant differences between the groups 
(Table 2). It is possible that the first group maintained bet-
ter therapy compliance or social support. Throughout the 
monitoring period, these two groups showed no significant 
differences in their scores on the following psychiatric tests: 
PANSS, CGI-S, TOL DX, LN, TMT-A, and PSP. The only 
exception was the NAA/Cr ratio after 12 months, which was 
significantly higher in the group that stayed on the same 
antipsychotic drug throughout the study course (median 
[IQR] 1.93 [1.87–2.27]) compared to the drug-changing 
group (1.70 [1.37–1.77]; P=0.006). As for the differences 
between paired measures (baseline versus month 12), the 
drug-changing group exhibited noteworthy dynamics: total 
PANSS score (P=0.001), positive PANSS score (P=0.001), 
general PANSS score (P=0.011), CGI-S score (P=0.018), 
Table 2 sociodemographic characteristics of the two investigated groups
More than one antipsychotic  
N=15
One antipsychotic  
N=10
P-value
Mean SD Percentiles Mean SD Percentiles
25th 50th (median) 75th 25th 50th (median) 75th
age, years 25.00 3.25 22.00 25.00 28.00 26.10 3.00 23.00 26.00 29.00 0.402
education, years 11.93 0.70 12.00 12.00 12.00 12.80 1.87 11.75 12.00 14.50 0.330
Duration of disease, months 23.73 14.71 11.00 21.00 38.00 24.90 7.50 18.75 24.00 27.50 0.560
Male sex: n (%)* 12 (80%) 8 (80%) 0.610
Note: *P0.05.
Abbreviations: sD, standard deviation; N, number of patients.
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and NAA/Cr (P=0.008) decreased, while LN score 
(P=0.001) and PSP score (P=0.001) increased (Table 3). 
In the group that stayed on the same antipsychotic drug 
throughout the study course, total PANSS score (P=0.032), 
positive PANSS score (P=0.009), negative PANSS score 
(P=0.027), and CGI-S score (P=0.025) decreased, while 
LN score (P=0.005), PSP score (P=0.008), and NAA/Cr 
(P=0.005) increased (Table 4).
Table 3 Differences in measured values found across the group taking more than one antipsychotic drug (N=15) – Wilcoxon test
Minimum Maximum 25th percentile Median 75th percentile
PaNss positive 0* 
PaNss positive 12*
12.00
8.00
28.00
15.00
13.00
10.00
17.00
11.00
19.00
13.00
PaNss negative 0
PaNss negative 12
12.00
16.00
31.00
27.00
20.00
17.00
21.00
21.00
26.00
22.00
PaNss general 0* 
PaNss general 12*
28.00
23.00
55.00
34.00
30.00
28.00
33.00
31.00
37.00
33.00
PaNss total 0* 
PaNss total 12*
59.00
49.00
114.00
75.00
65.00
57.00
72.00
62.00
81.00
69.00
cgi-s 0* 
cgi-s 12*
3.00
1.00
5.00
4.00
3.00
2.00
4.00
2.00
5.00
3.00
TOl DX 0
TOl DX 12
15.00
4.00
65.00
84.00
30.00
27.00
34.00
35.00
53.00
55.00
lN 0*
lN 12*
9.00
13.00
15.00
22.00
11.00
18.00
12.00
19.00
13.00
22.00
TMT-a 0
TMT-a 12
28.00
34.00
111.00
85.00
41.00
45.00
64.00
51.00
76.00
61.00
PsP 0* 
PsP 12*
45.00
63.00
80.00
84.00
55.00
68.00
60.00
73.00
70.00
76.00
Naa/cr 0* 
Naa/cr 12*
1.280
1.240
2.690
2.710
1.570
1.370
1.850
1.700
2.010
1.770
Note: *P0.05.
Abbreviations: cgi-s, clinical global impression of severity; cr, creatinine; lN, letter–Number span Test; Naa, N-acetylaspartate; PaNss, Positive and Negative 
syndrome scale; PsP, Personal and social Performance scale; TMT-a, Trail Making Test a; TOl DX, Tower of london – Drexel University.
Table 4 Differences in measured values found across the group sticking to the same antipsychotic drug throughout the study course 
(N=10) – Wilcoxon test
Minimum Maximum 25th percentile Median 75th percentile
PaNss positive 0* 
PaNss positive 12*
13.00
7.00
21.00
17.00
15.25
8.50
16.50
10.00
18.25
13.00
PaNss negative 0* 
PaNss negative 12*
17.00
16.00
29.00
27.00
20.00
17.00
23.50
21.00
25.50
22.25
PaNss general 0
PaNss general 12
27.00
24.00
44.00
42.00
29.00
28.75
33.50
30.50
40.50
33.50
PaNss total 0* 
PaNss total 12*
60.00
53.00
85.00
80.00
64.00
54.00
77.00
62.00
83.00
67.00
cgi-s 0* 
cgi-s 12*
3.00
1.00
5.00
4.00
3.00
2.00
4.00
3.00
5.00
3.00
TOl DX 0
TOl DX 12
23.00
7.00
55.00
78.00
30.00
15.00
41.50
24.50
49.00
58.00
lN 0*
lN 12*
4.00
15.00
17.00
21.00
8.00
17.00
10.00
18.50
12.00
19.00
TMT-a 0
TMT-a 12
38.00
37.00
109.00
81.00
44.00
43.00
66.00
51.00
83.00
72.00
PsP 0* 
PsP 12*
45.00
57.00
65.00
78.00
51.00
64.00
54.00
70.50
65.00
75.00
Naa/cr 0* 
Naa/cr 12*
1.360
1.640
2.100
2.590
1.620
1.880
1.685
1.925
1.820
2.180
Note: *P0.05.
Abbreviations: cgi-s, clinical global impression of severity; cr, creatinine; lN, letter–Number span Test; Naa, N-acetylaspartate; PaNss, Positive and Negative 
syndrome scale; PsP, Personal and social Performance scale; TMT-a, Trail Making Test a; TOl DX, Tower of london – Drexel University.
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In the group with more than one antipsychotic drug, 
significant negative correlations of NAA/Cr with PANSS 
positive and TOL DX score were found at the beginning of 
the study. After 12 months, NAA/Cr levels were significantly 
positive correlated with Hamilton Depression Rating Scale 
and LN scores.
At the beginning of the study in the group with only 
one antipsychotic drug, a significant correlation was noted 
between NAA/Cr and Hamilton Depression Rating Scale 
levels. After 12 months, significant and strong negative cor-
relations of NAA/Cr with CGI-S and TMT-A scores were 
found (Table 5).
Viewed on the whole-sample level, no significant cor-
relations between NAA/Cr values and other scores were 
seen either at baseline or after 12 study months. The same 
goes for the baseline status of the patients changing their 
antipsychotic drugs in the further course. After 12 study 
months, significant correlations between NAA/Cr and other 
scores were noted only among drug-switching patients, in 
whom a positive correlation with LN score was established 
(rho=0.617; P=0.014).
Discussion
This study failed to demonstrate any significant difference 
in NAA/Cr throughout the administration of the novel 
antipsychotic drug. Similar results were obtained in several 
recent studies.10,19 However, an intra-sample comparison 
of patients who favorably and swiftly responded to initial 
therapy with patients who needed two or more antipsychotic 
drugs (in order to attain a satisfactory therapeutic response) 
pointed towards different outcomes. Upon completion of 
the therapy, the first patient group showed a significant 
rise in NAA/Cr, both from baseline and compared to the 
 second patient group’s month 12 results. The second patient 
group not only failed to experience a rise in NAA/Cr, but 
also experienced a drop in NAA/Cr throughout the therapy 
course, despite the satisfactory end-study stage therapeutic 
response (Figure 2).
To the best of the authors’ knowledge, this is the very 
first follow-up study carried out in antipsychotic-naïve 
first-episode schizophrenic patients. The baseline scan was 
performed without any antipsychotic or other treatment 
except 5–10 mg diazepam for all patients. The differing 
Figure 1 a typical 1h spectrum and the spectroscopic volume of interest: left dorsolateral prefrontal cortical region.
Note: image from an outpatient of Polyclinic Neuron, croatian institute for Brain research (Zagreb, croatia).
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Table 5 Spearman’s correlation coefficients (rho) between functional outcome and NAA/Cr level at the beginning of the study 
and after 12 months
More than one antipsychotic N=15 One antipsychotic N=10
0 NAA/Cr 12 NAA/Cr 0 NAA/Cr 12 NAA/Cr
PaNss positive 0 rho
P-value
0.032
0.908
0.327
0.234
-0.414
0.235
-0.549
0.100
PaNss negative 0 rho
P-value
0.081
0.774
0.263
0.343
-0.079
0.828
-0.341
0.334
PaNss general 0 rho
P-value
-0.110
0.696
-0.017
0.952
0.188
0.602
-0.316
0.374
PaNss total 0 rho
P-value
0.105
0.708
0.288
0.298
0.079
0.829
-0.394
0.260
haM-D 0 rho
P-value
0.229
0.412
0.015
0.958
0.748
0.013
0.056
0.878
sas 0 rho
P-value
0.193
0.491
0.025
0.929
0.108
0.766
0.362
0.304
cgi-s 0 rho
P-value
-0.040
0.888
0.104
0.713
-0.360
0.307
-0.809
0.005
TOl DX 0 rho
P-value
-0.509
0.053
-0.195
0.485
0.207
0.567
0.286
0.424
lN 0 rho
P-value
-0.112
0.692
-0.068
0.810
-0.171
0.637
0.250
0.486
TMT-a 0 rho
P-value
-0.179
0.524
0.159
0.571
-0.418
0.229
-0.673
0.033
PsP 0 rho
P-value
-0.169
0.547
-0.337
0.219
0.148
0.684
0.412
0.236
PaNss positive 12 rho
P-value
-0.522
0.046
-0.422
0.118
0.233
0.517
-0.098
0.787
PaNss negative 12 rho
P-value
-0.250
0.368
-0.180
0.520
0.068
0.853
-0.006
0.987
PaNss general 12 rho
P-value
-0.392
0.148
-0.146
0.602
0.091
0.802
0.006
0.987
PaNss total 12 rho
P-value
-0.411
0.128
-0.202
0.470
0.245
0.496
-0.043
0.907
haM-D 12 rho
P-value
0.113
0.687
0.598
0.019
0.443
0.200
0.117
0.748
sas 12 rho
P-value
-0.148
0.600
-0.062
0.825
-0.007
0.984
0.052
0.886
cgi-s 12 rho
P-value
0.200
0.474
0.108
0.702
0.658
0.039
-0.111
0.761
cgi-i 12 rho
P-value
0.080
0.776
0.068
0.810
0.623
0.054
-0.159
0.661
TOl DX 12 rho
P-value
-0.586
0.022
-0.265
0.341
0.248
0.489
0.188
0.603
lN 12 rho
P-value
0.385
0.156
0.617
0.014
0.228
0.526
0.426
0.220
TMT-a 12 rho
P-value
-0.497
0.059
-0.023
0.934
-0.012
0.973
-0.480
0.160
PsP 12 rho
P-value
0.136
0.628
0.020
0.944
-0.134
0.713
0.146
0.688
Abbreviations: cgi-i, clinical global impression of improvement; cgi-s, clinical global impression of severity; cr, creatinine; haM-D, hamilton Depression rating scale; 
lN, letter-Number span Test; Naa, N-acetylaspartate; PaNss, Positive and Negative syndrome scale; PsP, Personal and social Performance scale; sas, simpson-angus 
scale; TOl DX, Tower of london – Drexel University; TMT-a, Trail Making Test a.
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Figure 2 comparison of Naa/cr levels between two groups that had more than one antipsychotic, or had one antipsychotic.
Notes: (A) Both groups showed improvement in total PaNss score. (B) in the drug-changing group, the Naa/cr ratio decreased; however, in the group sticking to the 
same antipsychotic drug, the Naa/cr ratio increased after 12 months.
Abbreviations: cr, creatinine; Naa, N-acetylaspartate; PaNss, Positive and Negative syndrome scale.
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results of the two groups might explain why the outcomes of 
previous studies vary to such a great extent. Differences in 
study outcomes could also be attributed to the differences in 
duration of the monitoring period, as well as the differences 
in sample sizes, selection of the target brain region, and the 
employed 1H MRS technique. In addition, the administered 
antipsychotic drugs were mutually different and given in 
various disease and treatment stages. The authors are fully 
aware of the limitations of this study, which can be attributed 
to the size of the studied sample. This was especially appar-
ent with the intra-sample patient grouping; however, the fact 
that the patients who stayed on a single antipsychotic drug 
throughout the monitoring period exhibited a unanimous 
rise in NAA/Cr levels deserves attention and should be 
considered indicative.
The current results correspond with those of another 
study which demonstrated a drop in NAA levels across the 
non-remitting patients and a rise in NAA levels across the 
remitting patients, even though a 28-day treatment of manic 
adolescents failed to yield any rise in total NAA levels.43 It is 
worth noting that the patients treated within the framework 
of the above study received olanzapine, which failed to yield 
a rise in NAA levels in the examinees (N=10) despite the 
achieved therapeutic response. That could be best explained 
by the fact that this study focused on patients with schizo-
phrenia, while the study in reference was comprised of type I 
bipolar disorder patients. The results could also be related to 
the affective basis of bipolar disorder.44 In addition, the NAA 
rise witnessed within the framework of the latter study is 
more likely to be attributed to the alleviation of manic symp-
toms than to the olanzapine-related therapeutic effects. Even 
though the patients in the current study were treated with 
more than one atypical antipsychotic drug and unanimously 
responded to treatment (thereby taking the study design into 
account), the rise in NAA/Cr levels was witnessed only in the 
quetiapine monotherapy arm. Such a finding, together with 
the lack of olanzapine-related therapeutic benefits, could be 
suggestive of differences in the acting mechanisms of various 
atypical antipsychotic drugs, at least when it comes to NAA. 
Pending additional research, of course, MRS might prove 
to be a useful guide for choosing the early-stage therapy of 
patients with schizophrenia. However, the fact that olanzap-
ine was the first administered and the last withdrawn drug in 
the study protocol – that is to say, the only drug administered 
to the study group throughout the entire 12-month study 
course – should not be neglected.
This study failed to reveal any substantial relationship 
between NAA/Cr and a psychopathology profile. The cor-
relation between the investigated variable and cognitive 
functioning is merely suggested by the positive correlation 
with LN scores, which was seen only at follow-up month 12 
and only in patients taking more than one antipsychotic 
drug. The absence of correlation between the investigated 
parameter and cognitive functioning could be attributed in 
part to a lower number of employed tests compared to some 
of the previous studies. That is, within the frame of the cur-
rent study, only rapid neuropsychological testing was carried 
out, mostly because of the patients’ profiles; on the occasion 
of the first testing, the patients were acute and antipsychotic 
medication-naïve.
While some of the studies from the introduction man-
aged to demonstrate a correlation between the alterations in 
1H MRS – established metabolite concentrations and vari-
ous symptoms (only in functionally-related brain regions, 
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 however), other studies failed to reveal such a specific pattern 
and operated on the presumption of wider white and gray 
matter damage inflicted by schizophrenia.45 Bustillo et al are 
of the opinion that studies investigating schizophrenia, which 
implies minor, albeit widespread, white and gray matter 
alterations, should aim to target wider brain regions.46
This is also a limitation of the current study, which tar-
geted one brain region only. Another limitation may be the 
sole availability of baseline and final MR scans. Additional 
scans would significantly contribute to a better understand-
ing of NAA/Cr study dynamics, especially when it comes to 
scores obtained with the employed battery of tests.47
Conclusion
In summary, a 1-year administration of atypical antipsy-
chotic drugs to antipsychotic-naïve patients failed to evoke 
any substantial rise in NAA/Cr. However, a significant 
increase in NAA/Cr levels was seen in patients who stayed 
on their initial antipsychotic medication, which yielded a 
favorable therapeutic response. Despite the limitations of 
the current study, this finding points towards a link between 
NAA/Cr levels and atypical antipsychotic medication, 
which should be further investigated within a broader 
framework.48
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